2023 Autumn Conference Posters
Click title to view pdf. Posters are listed in alphabetical order by first author.
Brady-Development and content validation of a seizure eDiary optimized for clinical trials: A partnership with industry epilepsy experts (Abstract)
Cohen-Optimizing automated objective speech technologies for measuring negative symptoms (Abstract)
Colbert-The effects of digital neuromodulation: Basket design clinical trial for signal detection (Abstract)
Dahlem-Evolution of digital therapeutics: Utilizing clinical trials, reverse translation, and in silico methods for enhanced product lifecycle management in chronic disorders with episodic manifestations (Abstract)
Daniel-The utility of enhanced data surveillance on the presence of data quality concerns in acute schizophrenia clinical trials. A post hoc analysis (Abstract)
Davis-The IMPACT study: A randomized placebo-controlled trial using an N-of-1 design (Abstract)
Dawson-Effects of repeated intravenous esketamine administration on affective biases (Abstract)
Di Cesare-A semantic scale analysis of instruments intended to evaluate psychedelic experience in clinical trials (Abstract)
Dougherty-Psilocybin therapy for treatment resistant depression: Prediction of clinical outcome by natural language processing (Abstract)
Efstathiadis-Automated assessment of PANSS interview quality (Abstract)
Engler-Eligibility review using the Mini International Neuropsychiatric Interview for inpatient schizophrenia trials: Usability & common issues (Abstract)
Evans-Words (and pronouns) matter: Increasing LGBTQIA+ representation and visibility in MDD clinical trials (Abstract)
Fan-Use of digital health technology tool to assess medication adherence in schizophrenia: The INTERACT study experience (Abstract)
Farmer-Mitigating inferential errors in external control data for rare genetic conditions affecting neurodevelopment (Abstract)
Gehrlach-Novel genetic in-vitro diagnostic test to predict efficacy of BH-200, a V1b antagonist, in major depressive disorder: a phase II randomized controlled trial (Abstract)
Geraci-Utilizing AI on data from anxiety and schizophrenia trials to identify causal clusters of variables for drug & placebo response using long range association learning to improve clinical trial outcomes (Abstract)
Karas-A Phase 2, multi-center, randomized, double-blind, parallel-group, dose-finding study to assess the effect of four doses of MM-120 for the treatment of anxiety symptoms: Rational and methods (Abstract)
Kindellan-Validating linguistic feature extraction across multiple languages using open source NLP tools (Abstract)
König-Objective measures of psychiatric symptoms through speech and visual features during clinical interaction (Abstract)
Kothare-Differentiating primary and secondary expressive negative symptoms for remote digital trials using a multimodal dialogue platform (Abstract)
Kott-Does the relationship between the BNSS and the PANSS negative factor score differ between negative symptom and acute exacerbation schizophrenia studies? (Abstract)
Kott-Screening Mini Mental State Examination assessment duration as a marker of possible score inflation (Abstract)
Lagler-Machine learning-supported ERP-based biomarker identification in MCI/AD (Abstract)
McCoy-Exploring novel executive functioning tasks for high-frequency testing using within- and across-task sensitivity (Abstract)
Meepegama-Speaker verification for remote self-assessments in clinical trials (Abstract)
Micaletto-Correlation between the Personal and Social Performance scale (PSP) and the Positive and Negative Syndrome Scale (PANSS) in a individual countries sample of patients with schizophrenia (Abstract)
Miller-Poor performance on diagnostic tests in early dementia clinical trials as a marker of possible score inflation. An exploratory analysis (Abstract)
Moore-Typing speed as a digital biomarker for processing speed among Hispanics/Latinos (Abstract)
Neumann-Towards an interpretable index score for the assessment of schizophrenia based on multimodal speech and facial biomarkers (Abstract)
Roy-How do threshold MADRS eligibility criteria influence MADRS scoring? (Abstract)
Schafer-Characterization of success rates and placebo response in clinical trials of pharmacotherapies for generalized anxiety disorder (Abstract)
Simmons-Utilizing experienced research networks to conduct global clinical trials in difficult to access populations for drug development in psychiatry (Abstract)
Taptiklis-Automated extraction of fatigue content from voice diary data (Abstract)
Veldsman-Ecological momentary analysis of high-frequency cognitive testing and its relationship to fatigue and sleep across neurodegenerative and inflammatory disorders (Abstract)
Veldsman-High compliance to remote, high-frequency cognitive testing across immune-mediated inflammatory disease and neurodegenerative disease patients (Abstract)
Viola-Assessing reliability and sensitivity of the Psychomotor Vigilance Task in a long-term longitudinal study of sleep EEG: the impact of task length on sleep-related measures (Abstract)
Weston-Automated scoring of logical memory test directly from audio recordings: Enhancing test reliability and reducing measurement noise (Abstract)
Wragg-Evaluating cognitive composite measures for power to detect treatment differences (Abstract)